IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
Study Details
Study Description
Brief Summary
The purpose of this study is to find the safest and most effective way to administer IV antibiotics to treat acute pulmonary exacerbations (APEs) in patients with cystic fibrosis (CF) that are caused by pathogens, like Pseudomonas aeruginosa. This study will test the safety and effectiveness of two commonly prescribed IV antibiotics: tobramycin and colistin. Though regularly used, not much is known about how these drugs compare with each other in terms of their toxicities, both during short term treatment of an APE and after many treatment courses with these drugs over many years. There are currently no guidelines on the safest and most effective antibiotics to use when treating APEs. We will study kidney function, sputum cultures, and treatment outcomes in patients receiving routine administration of one of these two IV antibiotics. We will also test these outcomes in patients receiving a less frequent dosing schedule for IV colistin. The hope is that this new schedule for IV colistin, which is twice a day and adjusted based on blood and urine tests, will reduce harmful side effects, such as kidney damage, while still being a powerful treatment against CF microbial pathogens.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Standard colistin arm Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule. |
Drug: Colistin
|
| Active Comparator: Modified colistin arm Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion). |
Drug: Colistin
|
| Active Comparator: Standard tobramycin arm Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes |
Drug: Tobramycin
|
Outcome Measures
Primary Outcome Measures
- absolute change in forced expiratory volume at one second (FEV1) % predicted between study arms with acute pulmonary exacerbation (APE) treatment [up to 14 days, from beginning to end of APE treatment]
- rate of occurrence of the development of acute kidney injury (AKI) during APE treatment [up to 14 days, from beginning to end of APE treatment]
Secondary Outcome Measures
- time to achievement of steady state with pharmacokinetic (PK)-adjusted colistin therapy [up to 14 days, from beginning to end of APE treatment]
- longitudinal differences in exacerbation rates and antimicrobial resistance between tobramycin and colistin use as seen in readmission rate and sputum culture results [from the beginning of APE treatment to 12 months after APE treatment]
- differences in occurrences of neurotoxicity and ototoxicity related side effects between study arms as reported by treating physician(s) [up to 14 days, from beginning to end of APE treatment]
- measurement of pharmacokinetics of colistin's active metabolites in a broad CF population through peak, trough, and midpoint blood draws [up to 14 days, from beginning to end of APE treatment]
- comparison of plasma pharmacokinetics of colistin's active metabolites with levels achieved in the sputum, in order to calculate epithelial lining fluid concentrations, through mass spectrometry [up to 14 days, from beginning to end of APE treatment]
- novel biomarkers of nephrotoxic AKI, prior to serum creatinine increases, based on urine protein:creatinine ratios [up to 14 days, from beginning to end of APE treatment]
- novel biomarkers of nephrotoxic AKI, prior to serum creatinine increases, based on the urine biomarker Nephrocheck® point-of-care assay [up to 14 days, from beginning to end of APE treatment]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female ≥ 18 years of age at Visit 1.
-
Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
-
Sweat chloride equal or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test.
-
Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
-
Abnormal nasal potential difference (NPD) as measured by a change in NPD in response to a low chloride solution and isoproterenol of less than -5 mV.
-
Documentation of the presence of an acute pulmonary exacerbation, based on CF Foundation guidelines, as diagnosed by a faculty member of the Denver Adult CF Program.
-
Respiratory culture(s) demonstrating evidence of Pseudomonas aeruginosa or Achromobacter species airway infection.
-
Subject is able to produce sputum, undergo phlebotomy, and provide written consent.
-
The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment. Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms. If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin.
Exclusion Criteria:
-
Concomitant administration of bactrim (due to effects on creatinine).
-
Concomitant administration of inhaled colistin for patients in the colistin PK arm, as this will create inaccuracies in colistin sputum concentration measurements.
-
Patients being treated for B. cepacia, due to colistin resistance by the pathogen.
-
Presence of chronic renal insufficiency, with abnormal baseline creatinine >1.2mg/dL.
-
Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
-
Inability to perform reproducible spirometry.
-
Inability to expectorate sputum. -
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Jewish Health | Denver | Colorado | United States | 80206 |
Sponsors and Collaborators
- National Jewish Health
Investigators
- Principal Investigator: Milene Saavedra, MD, National Jewish Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SAAVED15A0